Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Labcorp Declares Quarterly Dividend

2026-01-14
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12, 2026, to stockholders of record as of the close of business on February 27, 2026.

3 Value Stocks Walking a Fine Line

2026-01-14
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13
Labcorp Holdings Inc. (LH) 44th Annual J.P.

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

2026-01-13
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Lab

Assessing Labcorp Holdings (LH) Valuation After A Recent 10.5% Three Month Share Price Decline

2026-01-13
Recent trading in Labcorp Holdings (LH) has drawn attention after the stock showed a 10.5% decline over the past 3 months, prompting investors to reassess its current valuation and long term return profile. See our latest analysis for Labcorp Holdings. The recent 10.5% 3 month share price decline sits against a relatively steady year to date share price return of around flat, while the 1 year total shareholder return of 8.15% suggests momentum has cooled rather than collapsed. If Labcorp’s...

3 Value Stocks We Think Twice About

2026-01-13
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options

2026-01-13
Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRTWILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Testosterone replacement therapy requires evaluation by a licensed healthcare provider. If you access services through links in this article, a commission may be earned at no additional cost to yo

5 Considerations In The Upcoming CPI Report

2026-01-11
Stock indices rallied despite limited CPI data last month; since then, small-caps and Dow are outperforming tech into early 2026.

Labcorp’s Quarterly Earnings Preview: What You Need to Know

2026-01-09
Here’s what you need to know about Labcorp Holdings prior to its Q4 earnings release.

NAMSA acquires Labcorp’s medical device testing assets

2026-01-09
The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.